Search research articles
Contact Us
Filters
Showing results (891-900 of 1,012) with videos related to
Page
of 102
Sort By:
The Lancet. Oncology
|
November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Blood
|
January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Valeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2026
Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial
Prithviraj Bose, Haris Ali, Haifa Kathrin Al-Ali, et al.
Critical Reviews in Oncology/Hematology
|
November 19, 2018
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials
Mattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, et al.
Cancer
|
September 21, 2011
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients
Alessandro Gozzetti, Alfonso Cerase, Flavia Lotti, et al.
Cancer Medicine
|
November 26, 2024
Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study
K Mancuso, R Mina, S Rocchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Antonio Palumbo, Francesca Gay, Federica Cavallo, et al.
Hemasphere
|
December 31, 2025
Health-related quality of life and symptom profile of patients with <i>BCR::ABL1</i>-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study
Giovanni Caocci, Alessandro Costa, Francesca Palandri, et al.
Blood Advances
|
November 13, 2024
Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study
Bruno Fattizzo, Alfredo Marchetti, Alessandro Bosi, et al.
Cancer Medicine
|
April 1, 2024
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
Anna Furlan, Michele Cea, Laura Pavan, et al.
Page
of 102
Search research articles
Search
Showing results (891-900 of 1,012) with videos related to
Sort By:
Page
of 102
The Lancet. Oncology
|
November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Blood
|
January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Valeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2026
Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial
Prithviraj Bose, Haris Ali, Haifa Kathrin Al-Ali, et al.
Critical Reviews in Oncology/Hematology
|
November 19, 2018
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials
Mattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, et al.
Cancer
|
September 21, 2011
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients
Alessandro Gozzetti, Alfonso Cerase, Flavia Lotti, et al.
Cancer Medicine
|
November 26, 2024
Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study
K Mancuso, R Mina, S Rocchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Antonio Palumbo, Francesca Gay, Federica Cavallo, et al.
Hemasphere
|
December 31, 2025
Health-related quality of life and symptom profile of patients with <i>BCR::ABL1</i>-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study
Giovanni Caocci, Alessandro Costa, Francesca Palandri, et al.
Blood Advances
|
November 13, 2024
Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study
Bruno Fattizzo, Alfredo Marchetti, Alessandro Bosi, et al.
Cancer Medicine
|
April 1, 2024
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
Anna Furlan, Michele Cea, Laura Pavan, et al.
Page
of 102